Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04471415 |
Title | First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. |
Recruitment | Recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | Yes |
Sponsors | Dracen Pharmaceuticals, Inc. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ESP | DEU |